Bibliographie

1. Schoenmaker, L. et al., 2021, **"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability"**, https://doi.org/10.1016/j.ijpharm.2021.120586

2. Sato Yusuke, 2021, **"Development of Lipid Nanoparticles for the Delivery of Macromolecules Based on the Molecular Design of pH-Sensitive Cationic Lipids"**, *Chem. Pharm. Bull*. 69. 1141-1159

3. Vu, M. N. et al., 2021, **"Current and future nanoparticle vaccines for COVID-19",** https://doi.org/10.1016/j.ebiom.2021.103699

4. Szebeni, J. et al., 2022, **"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines"**, https://doi.org/10.1038/s41565-022-01071-x

5. Pardi, N. et al., 2018, **"mRNA vaccines – a new era in vaccinology"**, doi: 10.1038/nrd.2017.243

6. Kozma, G. T. et al., 2020, **"Anti-PEG antibodies : Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals"**, https://doi.org/10.1016/j.addr.2020.07.024

7. Janis Kuby et al., **« IMMUNOLOGY »**, 7ème édition, DUNOD

8. Chen, B. M. et al., 2016, **"Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals"**, *Anal. Chem.* 2016, 88, 21, 10661–10666, doi: 10.1021/acs.analchem.6b03109.

9. Hong, L. et al., 2020, **"Antibodies against polyethylene glycol in human blood: A literature review"**, *J Pharmacol Toxicol Methods*. Mar-Apr 2020;102:106678 https://doi.org/10.1016/j.vascn.2020.106678

10. Zhou, Z.-H. et al., **"Anti-PEG IgE In Anaphylaxis Associated with Polyethylene Glycol"**, doi: 10.1016/j.jaip.2020.11.011.

11. Janos Szebeni, 2014 **"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals"**, *Mol Immunol*. 2014 Oct;61(2):163-73. doi: 10.1016/j.molimm.2014.06.038.

12. Hydar Ali, 2010, **"Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a"**, https://doi.org/10.1016/j.imlet.2009.10.007

13. Shammas F. Bajwa; Reem Hamdy A. Mohammed, 2021 **"Type II Hypersensitivity Reaction"**, https://www.ncbi.nlm.nih.gov/books/NBK563264/

14. Norina Usman; Pavan Annamaraju, 2021, **"Type III Hypersensitivity Reaction"**, https://www.ncbi.nlm.nih.gov/books/NBK559122/

15. Ehlinger, C. et al., 2019, **"A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum"**, *J Immunol Methods*. 2019 Nov;474:112669. doi: 10.1016/j.jim.2019.112669.

16. Hiroto Hatakeyama, et al. 2011, **"A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma"**, *Adv Drug Deliv Rev*. 2011 Mar 18;63(3):152-60. doi: 10.1016/j.addr.2010.09.001.

17. Hiroto Hatakeyama, et al., 2013, **"The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors"**, *Biol Pharm Bull*. 2013;36(6):892-9. doi: 10.1248/bpb.b13-00059.

18. Buschmann, M. D. et al., 2021, **"Nanomaterial Delivery Systems for mRNA Vaccines"**, Vaccines, https://doi.org/10.3390/vaccines9010065

19. Samaridou, E. et al., 2020, **"Lipid nanoparticles for nucleic acid delivery: Current perspectives"**, https://doi.org/10.1016/j.addr.2020.06.002

20. Hou, X. et al., 2021, **"Lipid nanoparticles for mRNA delivery"**, *Nat Rev Mater* **6,** 1078–1094 (2021). https://doi.org/10.1038/s41578-021-00358-0

21. Reichmuth, A. M. et al., 2016, **"mRNA vaccine delivery using lipid nanoparticles"**, *Ther Deliv*. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006.

22. Li, C. et al., 2022, **"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine"**, Nature Immunology, VOL23, 543-555, https://doi.org/10.1038/s41590-022-01163-9

23. Dey, A. K. et al., 2021, **"Tuning the Immunostimulation Properties of Cationic Lipid Nanocarriers for Nucleic Acid Delivery"**, Front Immunol. 2021 Aug 23;12:722411. doi: 10.3389/fimmu.2021.722411.

24. Hervé, C. et al., 2019, **"The How's and What's of vaccine reactogenicity"**, *npj Vaccines* (2019)4:39; https://doi.org/10.1038/s41541-019-0132-6

25. Jackson, L. A. et al., 2020, **"An mRNA Vaccine against SARS-CoV-2 – Preliminary Report"** *N. Engl. J. Med.* 383, 1920-1931.

26. Sahin, U. et al., 2020, **"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 cell responses"** *Nature 586*, 594-599.

27. Walsh, E. E. et al., 2020, **"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates"**, *N. Engl. J. Med.* 383, 2439-2450.

28. Ndeupen, S. et al., 2021, **"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory"**, *iScience* 24, 103479, https://doi.org/j.isci.2021.103479

29. Sokol, C. L. et Luster, A. D., 2015, **"The Chemokine System in Innate Immunity"**, *Cold Spring Harb Perspect Biol* 2015;7:a016303, doi: 10.1101/cshperspect.a016303

30. Arunachalam, P. S. et al., 2021, **"Systems vaccinology of the BNT162b2 mRNA vaccine in humans"**, *Nature* **596,** 410–416 (2021). https://doi.org/10.1038/s41586-021-03791-x

31. Bergamaschi, C. et al., 2021, **"Systemic IL-15, IFN-γ, and IP10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients"**, *Cell Rep.* 2021 Aug 10.36(6):109504. doi: 10.1016/j.celrep.2021.109504.

32. Miyashita, Y. et al., 2022, **"Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination"**, npj Vaccines (2022)7:16; https://doi.org/10.1038/s41541-022-00439-3

33. Metzemaekers, M. et al., 2020, **"Neutrophils chemoattractant receptors in health and disease: double-edged swords"**, *Cellular & Molecular Immunology* 17:433-450; https://doi.org/10.1038/s41423-020-0412-0

34. Vazirinejad, R. et al., 2014, **"The Biological Functions, Structure and Sources of CXCL10 and Its Outstanding Part in the Pathophysiology of Multiple Sclerosis"**, *Neuroimmunomodulation* 2014;21:322-330; https://doi.org/10.1159/000357780

35. Jinquan, T. et al., 2000, **"CXCR3 Expression and Activation of Eosinophils : Role of IFN-γ-Inducible Protein-10 and Monokine Induced by IFN-γ"**, J Immunol 2000; 165:1548-1556; doi: 10.4049/jimmunol.165.3.1548

36. Tahtinen, S. et al., 2022, **"IL-1-mediated inflammation induced by different RNA vaccines is context-specific"**, *Nat Immunol* **23,** 485–486 (2022). https://doi.org/10.1038/s41590-022-01177-3

37. Sadarangani, M. et al., 2021, **"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans"**, Nature Reviews Immunology, volume 21, 475-484

38. Röltgen, K. et al., 2022, **"Immune impriting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination"**, Cell 185, 1-16; https://doi.org/10.1016/j.cell.2022.01.018

39. Elrod, S. et Stansfield, W., 2003, **« Génétique »** - ISBN : 2-10-006653 6

40. Bhurani V. et al., 2018, **"Developing effective vaccines: cues from natural infection"**, doi: 10.1080/08830185.2018.1471479

41. Chen, T.-H. et al., 2022, **"Improving the fidelity of uridine analog incorporation during in vitro transcription"**, https://doi.org/10.1101/2022.04.12.488100

42. Martinez, N. M. et al., 2022, **"Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing"**, https://doi.org/10.1016/j.molcel.2021.12.023

43. Seneff, S. et al., 2022, **"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs"**, doi: 10.1016/j.fct.2022.113008

44. Diamond, M. S. et Kanneganti, T.-D., 2022, **"Innate immunity: the first line of defense against SARS-CoV-2"**, *Nat Immunol* **23,** 165–176. https://doi.org/10.1038/s41590-021-01091-0

45. Zendjabil, M. et al., 2017, **"The microRNAs as biomarkers: What prospects?"**, https://doi.org/10.1016/j.crvi.2016.12.001

46. Broughton, J. P. et al., 2016, **"Pairing beyond the Seed Supports MicroRNA Targeting Specificity"**, *Mol Cell*. doi: 10.1016/j.molcel.2016.09.004.

47. O'Brien, J. et al., 2018, **"Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation"**, doi: 10.3389/fendo.2018.00402.

48. Barbu, M. G. et al., 2020, **"MicroRNA Involvement in Signaling Pathways During Viral Infection"**, https://doi.org/10.3389/fcell.2020.00143

49. Ahmad, I. et al., 2020, **"Viral MicroRNAs: Interfering the Interferon Signaling"**, https://doi.org/10.2174/1381612826666200109181238

50. Bansal, S. et al., 2021, **"Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer–BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines"**, https://doi.org/10.4049/jimmunol.2100637

51. Mishra, R. et Banerjea, A.C., 2021, **"SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia"**, doi: 10.3389/fimmu.2021.656700.

52. Schoggins, J. W. et Rice, C. M., 2011, **"Interferon-stimulated genes and their antiviral effector functions"**, doi: 10.1016/j.coviro.2011.10.008

53. Platanitis, E. et al., 2019, **"A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription"**, *Nat Commun* **10,** 2921 (2019). https://doi.org/10.1038/s41467-019-10970-y

54. Wang; E. et al., 2021, "**G-Quadruplexes as pathogenic drivers in neurodegenerative disorders"**, Nucleic Acids Research, Volume 49, Issue 9, 21 May 2021, Pages 4816–4830, https://doi.org/10.1093/nar/gkab164

55. Olsthoorn, René C. L., 2014, **"G-quadruplexes within prion mRNA: the missing link in prion disease?"**, Nucleic Acids Research, Volume 42, Issue 14, 18 August 2014, Pages 9327–9333, https://doi.org/10.1093/nar/gku559

56. Seneff, S. et Nigh, G, 2021, **"Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19"**, *International Journal of Vaccine Theory, Practice, and Research* 2(1), May 10, 2021

57. Xia, Xuhua, 2021, **"Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design"**, Viruses, 13(1), 109; https://doi.org/10.3390/v13010109

58. Alfagih, I. M. et al., 2020, **"Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines"**, doi: 10.3390/pharmaceutics13010045.

59. Di, J. et al., 2022, **"Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size"**, *Pharm Res* **39,** 105–114 (2022). https://doi.org/10.1007/s11095-022-03166-5

60. Kudsiova, L. et al., 2021, **"Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres"**. *BMJ Open Science* 2021;5:e100203. doi:10.1136/bmjos-2021-100203

61. Schädlich, A. et al., 2012, **"Accumulation of nanocarriers in the ovary: A neglected toxicity risk?"**, https://doi.org/10.1016/j.jconrel.2012.02.012

62. Ajdary, M. et al., 2021, **"Potential toxicity of nanoparticles on the reproductive system animal models: A review"**, https://doi.org/10.1016/j.jri.2021.103384

63. Riley, R. S. et al., 2021, **"Ionizable lipid nanoparticles for in utero mRNA delivery"**, *Sci. Adv*. 2021;7:eaba1028

64. Breton, Gaëlle, 2017, **"De la diversité des cellules dendritiques humaines"**, m/s n° 10, vol. 33, octobre 2017 doi : 10.1051/medsci/20173310003

65. Krystel-Whittemore, M. et al., 2016, **"Mast Cell: A Multi-Functional Master Cell"**, https://doi.org/10.3389/fimmu.2015.00620

66. Peter F. Weller and Lisa A. Spencer, 2017, **"Functions of tissue-resident eosinophils"**, doi: 10.1038/nri.2017.95

67. Crinier, A. et al., 2017, **"Innate lymphoid cells"**, https://doi.org/10.1051/medsci/20173305018

68. Cherrier, Marie, **"Innate lymphoid cells: new players of the mucosal immune response"**, *Med Sci* (Paris) 2014 ; 30 : 280–288. doi: 10.1051/medsci/20143003016.

69. Moretta, A. et al., 2001, **"Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis"**, doi: 10.1146/annurev.immunol.19.1.197.

70. Cortez, V. S. et al., 2014, **"Cutting edge: Salivary gland NK cells develop independently of Nfil3 in steady-state"**, J Immunol 2014 ; 192 : 4487–4491. doi: 10.4049/jimmunol.1303469

71. Wosczyna, M. N. et al., 2019, **"Mesenchymal Stromal Cells Are Required for Regeneration and Homeostatic Maintenance of Skeletal Muscle"**, Cell Reports 27, 2029-2035, https://doi.org/10.1016/j.celrep.2019.04.074

72. Messing, M. et al., 2020, **"Group 2 Innate Lymphoid Cells: Central Players in a Recurring Theme of Repair and Regeneration"**, *Int. J. Mol. Sci.* 2020, 21, 1350; doi:10.3390/ijms21041350

73. Gronke, K. et al., 2016, **"Innate lymphoid cells, precursors and plasticity"**, doi: 10.1016/j.imlet.2016.07.004.

74. Robinette, M.L. et al., 2017, **"IL-15 sustains IL-7R-independent ILC2 and ILC3 development"**, *Nat Commun* **8,** 14601 (2017). https://doi.org/10.1038/ncomms14601

75. Vanoni, G. et al., 2021, **"Human primed ILCPs support endothelial activation through NF-κB signaling"**, doi: 10.7554/eLife.58838.

76. Hackel, A. et al., 2021, **"TNF-α and IL-1β sensitize human MSC for IFN-γ signaling and enhance neutrophil recruitment"**, *Eur. J. Immunol*. 51: 319–330 doi: 10.1002/eji.201948336

77. Ullah, I. et al., 2015, **"Human mesenchymal stem cells - current trends and future prospective"**, doi: 10.1042/BSR20150025

78. Orimo, K. et al., 2021, **"Characteristics of tissue–resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory diseases"**, https://doi.org/10.1111/all.14863

79. Romero-Suárez, S. et al., 2019, **"The Central Nervous System Contains ILC1s That Differ From NK Cells in the Response to Inflammation"**, https://doi.org/10.3389/fimmu.2019.02337

80. Doisne, J.-M. et al., 2015, **"Composition, Development, and Function of Uterine Innate Lymphoid Cells"**, doi: 10.4049/jimmunol.1500689

81. Mendes, J. et al., 2020, **"Innate Lymphoid Cells in Human Pregnancy"**, doi: 10.3389/fimmu.2020.551707

82. Wang, W. et al., 2020, **"T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells"**, doi: 10.3389/fimmu.2020.02025

83. Laresgoiti-Servitje, E., 2013, **"A leading role for the immune system in the pathophysiology of preeclampsia"**, doi: 10.1189/jlb.1112603

84. Eghbal-Fard, S. et al., 2019, **"The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia"**, doi: 10.1002/jcp.27315.

85. Carson, W. E. et al., 1994, **"Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor"**, doi: 10.1084/jem.180.4.1395.

86. Ivashkiv, Lionel B., 2018, **"IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy"**, *Nat Rev Immunol* 18, 545–558 (2018). https://doi.org/10.1038/s41577-018-0029-z

87. Sahin, U. et al., 2020, "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses", *Nature* **586,** 594–599. https://doi.org/10.1038/s41586-020-2814-7

88. Oberhardt, V. et al., 2021, **"Rapid and stable mobilization of CD8⁺ T cells by SARS-CoV-2 mRNA vaccine"**, *Nature* **597,** 268–273. https://doi.org/10.1038/s41586-021-03841-4

89. Avci, E. et Abasiyanik, F., 2021, **"Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up?"** *J Autoimmun*. doi: 10.1016/j.jaut.2021.102745.

90. Boettler, T. et al., 2022, **"SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis"**, https://doi.org/10.1016/j.jhep.2022.03.040

91. Chen, Y. et al., 2021, **"New-onset autoimmune phenomena post-COVID-19 vaccination"**, https://doi.org/10.1111/imm.13443

92. Kobiyama R. & Ishii K.J., 2022, **"Making innate sense of mRNA vaccine adjuvanticity"**, *Nat Immunol* **23,** 474–476. https://doi.org/10.1038/s41590-022-01168-4

93. Horton, N. C. et Mathew, P. A., 2015, **"NKp44 and Natural Cytotoxicity Receptors as Damage-Associated Molecular Pattern Recognition Receptors"**, doi: 10.3389/fimmu.2015.00031

94. Wu, Y. et al., 2017, **"Developmental and Functional Control of Natural Killer Cells by Cytokines"**, doi: 10.3389/fimmu.2017.00930

95. Hagemann, K. et al., 2022, "**Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients"**, https://doi.org/10.1002/eji.202149470

96. Vivier, E. et al., 2011, **"Innate or Adaptive Immunity? The Example of Natural Killer Cells"**, Science. doi: 10.1126/science.1198687

97. Jacob, J. et al., 1991, **"In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations"**, J Exp Med. doi: 10.1084/jem.173.5.1165.

98. Amélie Bonaud, thèse 2015, **"Maturation finale des lymphocytes B : de la commutation de classe aux conséquences pathologiques de la production d'immunoglobulines anormales"**

99. Levin, E. G. et al., Déc. 2021, **"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months"**, N Engl J Med 2021; 385:e84, doi: 10.1056/NEJMoa2114583

100. Wu, Y. et al., 2016, **"The Biological Effects of IL-21 Signaling on B-Cell-Mediated Responses in Organ Transplantation"**, https://doi.org/10.3389/fimmu.2016.00319

101. Leonard, W. J. et Wan, C.-K., 2016, **"IL-21 Signaling in Immunity"**, doi: 10.12688/f1000research.7634.1

102. Skak, K. et al., 2008, **"Interleukin 21: combination strategies for cancer therapy"**, doi: 10.1038/nrd2482.

103. Korn, T. et al., 2007, **"IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells"**, https://doi.org/10.1038/nature05970

104. Poholek, C. H. et al., 2019, **"IL-21 Controls ILC3 Cytokine Production and Promotes a Protective Phenotype in a Mouse Model of Colitis"**, https://doi.org/10.4049/immunohorizons.1900005

105. Markota, A. et al., 2018, **"Targeting interleukin-22 for cancer therapy"**, https://doi.org/10.1080/21645515.2018.1461300

106. St. Paul, M. et al., 2020, **"IL6 Induces an IL22^{+} CD8^{+} T-cell Subset with Potent Antitumor Function"**, *Cancer Immunol Res*; 8 (3): 321–333. https://doi.org/10.1158/2326-6066.CIR-19-0521

107. Miyazaki, Y. et al., 2018, **"Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis"**, https://doi.org/10.3389/fimmu.2018.02901

108. Dudakov, J. A. et al., 2015, **"Interleukin-22: immunobiology and pathology"**, doi: 10.1146/annurev-immunol-032414-112123.

109. Cerboni, S. et al., 2020, **"Cytokine-regulated Th17 plasticity in human health and diseases"**, https://doi.org/10.1111/imm.13280

110. Jang, D.-i. et al., 2021, **"The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics"**, https://doi.org/10.3390/ijms22052719

111. Koumaki, D. et al., 2022, **"Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre"**, JEADV 2022, 36, e399–e496

112. Cortonesi, G. et al., 2022, **"New-onset psoriasis after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine successfully treated with ixekizumab"**, https://doi.org/10.1111/dth.15606

113. Pesqué, D. et al., 2022, **"New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin?"**, *Acad Dermatol Venereol*. 2022; 36(2): e80- e81. doi:10.1111/jdv.17690

114. Pavia, G et al., 2022, **"Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab"**, *Acad Dermatol Venereol*. 2022;18032. doi:10.1111/jdv.18032

115. Krajewski, P. K. et al., **"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine."** *J Eur Acad Dermatol Venereol*. 2021; 35(10): e632-e634. doi:10.1111/jdv.17449

116. McMahon, D. E. et al., 2021, **"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases."** *J Am Acad Dermatol*. 2021; 85(1): 46- 55. doi:10.1016/j.jaad.2021.03.092

117. Hwang J.H., 2022, **"Uveitis after COVID-19 Vaccination"**, https://doi.org/10.1159/000521785

118. Rabinovitch, T. et al., 2021, **"Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association"**, *Retina*. 2021;41(12):2462–713.

119. Renisi, G. et al., 2021, **"Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?"**, doi: 10.1016/j.ijid.2021.07.035.

120. Duran, M., 2022, "**Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report"**, https://doi.org/10.1016/j.jfo.2022.04.004

121. Li, C. X. et al., 2016, **"CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation"**, https://doi.org/10.1016/j.jhep.2016.05.032

122. Kingsley, I. E. et al., 2017, **"T regulatory cells follow CXCL10 to suppress T effector cells through a contact-dependent mechanism in the skin during vitiligo"**, *J Immunol May* 1, 2017, 198 (1 Supplement) 156.7

123. Dat Q. Tran, 2011, **"TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells"**, *Journal of Molecular Cell Biology*, Volume 4, Issue 1, Pages 29–37, https://doi.org/10.1093/jmcb/mjr033

124. Robin D Hatton, 2011, **"TGF-b in Th17 cell development: the truth is out there"**, doi: 10.1016/j.immuni.2011.03.009

125. Asadzadeh; Z. et al., 2017, **"The paradox of Th17 cell functions in tumor immunity"**, https://doi.org/10.1016/j.cellimm.2017.10.015

126. Karpisheh, V. et al., 2022, **"The role of Th17 cells in the pathogenesis and treatment of breast cancer"**, doi: 10.1186/s12935-022-02528-8.

127. Karki, R. et al., 2021, **"Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes"**, https://doi.org/10.1016/j.cell.2020.11.025

128. Grome, H. N. et al., 2021, **"Fatal Multisystem Inflammatory Syndrome in Adult after SARS-CoV-2 Natural Infection and COVID-19 Vaccination"**, doi: 10.3201/eid2711.211612

129. Stappers, S. et al., 2021, **"A case of multisystem inflammatory syndrome (MIS-A) in an adult woman 18 days after COVID-19 vaccination"**, *Acta Clin Belg*. doi:10.1080/17843286.2021.1977899.

130. Miyazato, Y. et al., 2022, **"Multisystem Inflammatory Syndrome in Adult after First Dose of mRNA Vaccine"**, doi: 10.3201/eid2804.212585.

131. Nune, A. et al., 2021, **"Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V)"** doi: 10.1136/bcr-2021-243888.

132. Abdelgalil, A. A. et Saeedi, F. A., 2022, **"Multisystem Inflammatory Syndrome in a 12-Year-old Boy After mRNA-SARS-CoV-2 Vaccination"**, doi: 10.1097/INF.0000000000003442.

133. Yalçinkaya, R. et al., 2022, **"A Case of Multisystem Inflammatory Syndrome in a 12-Year-old Male After COVID-19 mRNA Vaccine"**, doi: 10.1097/INF.0000000000003432.

134. Meriem Riani, thèse de 2017, **"Rôle de la chimiokine CXCL10 dans la réaction inflammatoire associée à l'autoimmunité : exemple de la pemphigoïde bulleuse"**

135. Afacan, E. et al., 2022, **"Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center"**, https://doi.org/10.1111/ijd.16086

136. Alshammari, F. et al., 2022, **"Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report"**, https://doi.org/10.1016/j.amsu.2022.103420

137. Maronese, C. A. et al., 2022, **"Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study"**, https://doi.org/10.3389/fmed.2022.841506

138. Jacobi, H.H. et al., 1998, **"IL-8 and the Activation of Eosinophils and Neutrophils following Nasal Allergen Challenge"**, https://doi.org/10.1159/000023925

139. Barnes, T. C. et al., 2011, **"The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis"**, doi: 10.1155/2011/721608

140. Choy, E. et Rose-John, S., 2017, **"Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis"**, https://doi.org/10.5301/jsrd.5000265

141. Jing Wang, 2018, **"Neutrophils in tissue injury and repair"**, doi: 10.1007/s00441-017-2785-7

142. Li, Y. et al., 2019, **"The regulatory roles of neutrophils in adaptive immunity"**, https://doi.org/10.1186/s12964-019-0471-y

143. Pelletier, M. et al., 2009, **"Evidence for a cross-talk between human neutrophils and Th17 cells"**, https://doi.org/10.1182/blood-2009-04-216085

144. Wilson, A. S. et al., 2022, **"Neutrophil extracellular traps and their histones promote Th17 cell differentiation directly via TLR2"**, *Nat Commun* **13,** 528 (2022). https://doi.org/10.1038/s41467-022-28172-4

145. Báez-Negrón, L. et Vilá, L. M., 2022, "**New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination"**, https://doi.org/10.1155/2022/6436839

146. Lemoine, C. et al., 2022, **"Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report"**, https://doi.org/10.1007/s10067-022-06126-x

147. Awad, A. et al., 2014, **"Natural Killer Cells Induce Eosinophil Activation and Apoptosis"**, https://doi.org/10.1371/journal.pone.0094492

148. Lombardi, C. et al., 2022, **"The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions"**, doi: 10.1016/j.crimmu.2022.03.002

149. da Costa Silva, J. et al. 2021, **"Neutrophil and Eosinophil DNA Extracellular Trap Formation: Lessons From Pathogenic Fungi"**, https://doi.org/10.3389/fmicb.2021.634043

150. Simon, H.-U. et al., 2020, **"The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum**", doi: 10.1159/000504847.

151. Lin, L. et al., 2018, **"Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid"**, doi: 10.1016/j.jid.2017.11.031.

152. Costanzo, G. et al., 2022, **"Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report"**, doi: 10.3390/vaccines10010013

153. Ameratunga, R. et al., 2022, **"First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction"**, https://doi.org/10.1007/s10875-021-01187-0

154. Brightling, C. E. et al., 2005, **"The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle"**, *Am J Respir Crit Care Med*. doi: 10.1164/rccm.200409-1220OC.

155. Galli, S. J. et al., 2012, **"IgE and mast cells in allergic disease"**, *Nat. Med*. 18, 693-704.

156. Gauthier, M. et al., 2017, **"Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias"**, https://doi.org/10.1172/jci.insight.94580

157. Van Anh Do-Thi, et al., 2020, **"Crosstalk between the Producers and Immune Targets of IL-9"**, doi: 10.4110/in.2020.20.e45

158. Fawaz, L. M. et al., 2007, **"Expression of IL-9 receptor α chain on human germinal center B cells modulates IgE secretion."**, J Allergy Clin Immunol.;120:1208–1215.

159. Weaver, C. T. et al., 2013, **"The Th17 Pathway and Inflammatory Diseases of the Intestines, Lungs and Skin"**, doi:10.1146/annurev-pathol-011110-130318.

160. Jinfang Zhu, 2018, **"T Helper Cell Differentiation, Heterogeneity, and Plasticity"**, doi: 10.1101/cshperspect.a030338

161. Ssemaganda, A. et al., 2022, **"Expansion of cytotoxic tissue-resident CD8$^+$ T cells and CCR6$^+$CD161$^+$ CD4$^+$ T cells in the nasal mucosa following mRNA COVID-19 vaccination"**, *Nat Commun* **13,** 3357. https://doi.org/10.1038/s41467-022-30913-4